Skip to content Skip to menu

Medicines Australia welcomes new AusBiotech CEO

Thursday, 3 May 2018

Media Release

Medicines Australia (MA) congratulates Lorraine Chiroiu on her appointment to CEO of AusBiotech.  After eight years with AusBiotech in various roles, most recently as Deputy CEO, Ms Chiroiu is extremely well qualified to lead the organisation in its continuing representation of the life sciences industry.

Interim CEO of MA, Ms Elizabeth de Somer said, “I look forward to working with Lorraine to continue, and strengthen, the collaboration between our organisations.  Lorraine will be an excellent voice for the biotechnology industry while her experience means the sector is in good hands.”

MA thanks Mr Glenn Cross, CEO of AusBiotech since 2016, for working constructively and openly with MA on a range of issues impacting both the life sciences and innovative medicines sectors.

Ms de Somer also said, “Under Glenn’s direction, both our organisations have constructively worked in parallel on common issues such as Intellectual Property rights, promoting Australia as a destination for clinical trials, and data protection for biologic medicines.  I wish Glenn success with his future.”

-END-

CONTACT: Kim Bessell

Ph. 0423 781 291

Email: kbessell@medaus.com.au

 

Information

As COVID19 continues to spread, our thoughts go out to anyone who has been infected or impacted. We hope that you are taking the necessary precautions to keep safe and well, both at work and at home.

Medicines Australia continues to monitor the situation and take advice from the Department of Health and the World Health Organisation. We are focused on responding to the important short-term issues but are also ensuring we stay balanced and maintain a focus on the medium and long-term business for our industry along with the well-being of our people.

At Medicines Australia we have initiated the following to ensure we support containment measures to provide business continuity and the well-being of our staff.

  • All non-essential travel has been restricted or cancelled
  • All face-to-face meetings (with external stakeholders and members) have been changed to virtual meetings (where appropriate)
  • Staff have been provided with the latest official information on COVID-19 through a hot-link on the office intranet; this information is regularly monitored and updated
  • Flexible working arrangements are covered in our HR policy which will allow staff to work remotely, if or when required
  • Current IT infrastructure enables staff to work remotely and will be in use if any person needs to self-isolate
  • Visual reminders have been displayed around the office, providing information about best hygiene practices
  • Extra hand-sanitiser, tissues and cleaning products have been supplied to staff for their work spaces

Our latest information is located at medicinesaustralia.com.au/covid-19/

Top